In a presentation at the Society for Immunotherapy of Cancer (SITC) meeting Friday, CAR T cell pioneer Carl June highlighted preclinical data from University of Pennsylvania suggesting CAR T cell therapies could require as little as three days of culture time, and shorter cultures could actually improve the cells' antitumor effects in vivo.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,